• Testosterone Bounce as a Prognostic Biomarker in Degarelix T

  2026-05-25

  A multicenter retrospective study demonstrates that 'testosterone bounce'—a transient rise in serum testosterone above 20 ng/dL after initial suppression—predicts improved overall and cancer-specific survival in prostate cancer patients treated with the GnRH receptor antagonist Degarelix acetate. This finding highlights a novel, actionable biomarker for refining prognosis and therapeutic monitoring in advanced prostate cancer.

• Dual Enzyme-Responsive Zwitterionic Peptides for Cancer Sele

  2026-05-24

  This study introduces a zwitterionic peptide amphiphile that leverages sequential activation by MMP-7 and cathepsin B to achieve highly selective cancer cell targeting via intralysosomal self-assembly. The dual enzyme-responsiveness results in a markedly high cancer selectivity index and demonstrates potent in vivo efficacy with minimal toxicity.

• Canagliflozin: SGLT2 Inhibitor Workflows for Mitochondrial R

  2026-05-23

  Canagliflozin, a potent SGLT2 inhibitor from APExBIO, enables refined modeling of renal glucose reabsorption and mitochondrial bioenergetics in diabetes research. This article delivers actionable protocols, troubleshooting strategies, and translational insights for leveraging Canagliflozin in advanced metabolic and nephrology workflows.

• BI 2536: Protocol-Driven PLK1 Inhibitor for Cancer Research

  2026-05-22

  BI 2536 stands out as a gold-standard PLK1 inhibitor, enabling precise induction of G2/M arrest and apoptosis in cancer cells. This article details validated workflows, actionable troubleshooting, and novel insights from the latest reference study, empowering researchers to optimize both in vitro and in vivo applications.

• Tariquidar (XR9576): Mechanobiology Meets Drug Resistance Re

  2026-05-22

  This thought-leadership article explores the intersection of tumor mechanobiology and transporter-driven chemoresistance, focusing on the strategic application of Tariquidar (XR9576) for translational research. Integrating mechanistic insight with actionable guidance, it highlights how high-viscosity microenvironments upregulate P-gp, the role of Tariquidar in overcoming such resistance, and evolving protocols to empower next-generation cancer drug development.

• ICG001: Applied Workflows for Wnt/β-Catenin Pathway Inhibiti

  2026-05-21

  ICG001 enables precise modulation of the Wnt/β-catenin signaling axis, empowering researchers to dissect EMT and fibrosis mechanisms with robust selectivity. This guide delivers actionable protocols, troubleshooting strategies, and data-driven insights for maximizing experimental clarity in disease modeling.

• Dasatinib (BMS-354825): Applied Kinase Inhibition in Cancer

  2026-05-21

  Dasatinib (BMS-354825) enables precise inhibition of Src and Bcr-Abl kinases, empowering advanced cancer research across diverse cellular and in vivo models. This article translates recent mechanistic insights into practical workflows, spotlighting troubleshooting strategies for robust, reproducible results.

• Ganetespib (STA-9090): Optimizing Hsp90 Inhibition in Cancer

  2026-05-20

  Unlock the full experimental potential of Ganetespib (STA-9090) for precise Hsp90 chaperone disruption in diverse cancer models. This article offers actionable protocols, advanced troubleshooting, and workflow enhancements to drive data-rich tumor growth inhibition and mechanistic studies.

• Ridaforolimus (Deforolimus): mTOR Inhibition and Senescence

  2026-05-20

  Explore Ridaforolimus (Deforolimus) as a potent mTOR inhibitor for advanced cancer and senescence research. This article uniquely bridges mechanistic detail with assay innovation and senolytic discovery, offering new perspectives for experimental design.

• Miltefosine in Hematology: Dual Pathway Modulation for Leuko

  2026-05-19

  A comprehensive, evidence-backed exploration of Miltefosine’s dual role as a PI3K/Akt inhibitor and Ras/MEK/ERK pathway activator, highlighting its transformative potential in translational hematology and leukopenia therapy. This article offers mechanistic depth, protocol guidance, and strategic insights for researchers seeking to bridge bench findings with clinical impact.

• β-Amanitin for RNA Polymerase II Studies: Optimized Workflow

  2026-05-19

  β-Amanitin, a highly selective RNA polymerase II inhibitor, is revolutionizing transcriptional regulation research by enabling precise mRNA synthesis inhibition assays and advanced toxicology modeling. This guide delivers actionable experimental protocols, troubleshooting insights, and highlights a breakthrough in rapid toxin detection—empowering molecular biologists and toxicologists with rigor and reproducibility.

• Cy3 Goat Anti-Mouse IgG (H+L) Antibody: Practical Lab Guide

  2026-05-18

  The Cy3 Goat Anti-Mouse IgG (H+L) Antibody provides a reliable, affinity-purified secondary reagent for sensitive detection of mouse primary antibodies in immunofluorescence, western blotting, and flow cytometry. This product is well suited for workflows requiring signal amplification but should not be used for diagnostic or medical purposes, nor outside validated immunoassay contexts.

• InstaBlue Protein Stain Solution: Rapid Protein Visualizatio

  2026-05-18

  InstaBlue Protein Stain Solution enables ultra-fast, sensitive protein detection in polyacrylamide gels, streamlining workflows by removing fixation and destaining steps. Its non-toxic, mass spectrometry-compatible formulation preserves protein integrity, making it ideal for advanced biomedical research and proteomics applications.

• ER Stress and Prometastatic States: Origins of Metastatic Tu

  2026-05-17

  Conod et al. (2022) uncover how tumor cells surviving near-lethal stress acquire stable prometastatic phenotypes, orchestrated via ER stress, nuclear reprogramming, and a multifactorial cytokine storm. These findings challenge conventional views on metastasis and have significant implications for cancer therapy and experimental modeling.

• Pemetrexed (A4390): Mechanisms and Evidence in Cancer Resear

  2026-05-16

  Pemetrexed, a multi-targeted antifolate antimetabolite, is widely used in cancer chemotherapy research for its ability to inhibit key enzymes in nucleotide biosynthesis. Its efficacy in non-small cell lung carcinoma and malignant mesothelioma models is well-documented. This article provides a factual, protocol-oriented overview of its mechanism, evidence base, and experimental application limits.

451 records 17/31 page Previous Next First page 上5页 1617181920 下5页 Last page